SEC Form 4 · accession 0000903423-15-000337
Foundation Medicine, Inc. · FMI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Krishna Yeshwant
Director · 10% Owner
Period of report
May 14, 2015
Accepted (ET)
May 18, 2015 · 8:59 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001488613
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | May 14, 2015 | S | 8,600 | $38.57 | D | 183,860 | I | See footnotes |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.50 to $38.78, inclusive. The Reporting Person undertakes to provide to Foundation Medicine, Inc., any security holder of Foundation Medicine, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
- F2These shares are directly held by Google Ventures 2011, L.P. The general partner of Google Ventures 2011, L.P. is Google Ventures 2011 GP, L.L.C. The Reporting Person is a partner at an affiliate of Google Ventures 2011 GP, L.L.C. and disclaims beneficial ownership of all shares except to the extent of his pecuniary interest, if any, therein.
- F3Solely as a result of the Investor Rights Agreement filed as Exhibit 4.1 of the Form 8-K filed by Issuer with the Securities and Exchange Commission on January 12, 2015 and the Reporting Person's position as a partner at an affiliate of Google Ventures 2011 GP, L.L.C., the Reporting Person may be deemed to have beneficial ownership of the (a) 20,604,288 shares directly held by Roche Holdings, Inc., an indirect wholly owned subsidiary of Roche Holding Ltd ("Roche" and together with Roche Holdings, Inc. and Roche Finance Ltd, the "Roche Entities"), (b) 414,823 shares directly held by Roche Finance Ltd, a wholly owned subsidiary of Roche and (c) shares previously held by Third Rock Ventures, L.P. ("TRV"). The Reporting Person disclaims beneficial ownership of any shares of Issuer held by any of the Roche Entities and TRV.